Literature DB >> 22382693

The role of procalcitonin in respiratory infections.

Laura Certain1, Philipp Schuetz.   

Abstract

Accurate diagnosis, risk stratification, and decisions about the need for and optimal duration of antibiotic therapy are cornerstones of the management of patients with respiratory infections. A growing body of evidence supports the use of procalcitonin, a marker of bacterial infection, in addition to conventional clinical parameters to improve diagnostic and prognostic assessment in patients with suspicion of respiratory infections. In addition, several randomized controlled trials indicate that procalcitonin may be used for clinical decision making about initiation and optimal duration of antibiotic therapy. For patients with respiratory infections, procalcitonin-guided antibiotic therapy resulted in less antibiotic use without any apparent adverse patient outcome. For other infections outcome studies are currently lacking. This review summarizes the results of recent investigations of procalcitonin in respiratory infections to provide physicians an overview of the utility and limitations of procalcitonin when used for bedside decision making.

Entities:  

Year:  2012        PMID: 22382693     DOI: 10.1007/s11908-012-0249-5

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  86 in total

1.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Authors:  Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

2.  Usefulness of serum procalcitonin levels in pulmonary tuberculosis.

Authors:  M Ugajin; S Miwa; M Shirai; H Ohba; T Eifuku; H Nakamura; T Suda; H Hayakawa; K Chida
Journal:  Eur Respir J       Date:  2010-06-07       Impact factor: 16.671

Review 3.  Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis.

Authors:  H Tang; T Huang; J Jing; H Shen; W Cui
Journal:  Infection       Date:  2009-10-13       Impact factor: 3.553

Review 4.  Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation.

Authors:  Daren K Heyland; Ana P Johnson; Steven C Reynolds; John Muscedere
Journal:  Crit Care Med       Date:  2011-07       Impact factor: 7.598

5.  Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial.

Authors:  Jens U Jensen; Lars Hein; Bettina Lundgren; Morten H Bestle; Thomas T Mohr; Mads H Andersen; Klaus J Thornberg; Jesper Løken; Morten Steensen; Zoe Fox; Hamid Tousi; Peter Søe-Jensen; Anne Ø Lauritsen; Ditte Strange; Pernille L Petersen; Nanna Reiter; Søren Hestad; Katrin Thormar; Paul Fjeldborg; Kim M Larsen; Niels E Drenck; Christian Ostergaard; Jesper Kjær; Jesper Grarup; Jens D Lundgren
Journal:  Crit Care Med       Date:  2011-09       Impact factor: 7.598

6.  Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children.

Authors:  P Toikka; K Irjala; T Juvén; R Virkki; J Mertsola; M Leinonen; O Ruuskanen
Journal:  Pediatr Infect Dis J       Date:  2000-07       Impact factor: 2.129

Review 7.  Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations.

Authors:  Sofya Tokman; Philipp Schuetz; Stephen Bent
Journal:  Expert Rev Anti Infect Ther       Date:  2011-06       Impact factor: 5.091

8.  Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial.

Authors:  Martin Stocker; Matteo Fontana; Salhab El Helou; Karl Wegscheider; Thomas M Berger
Journal:  Neonatology       Date:  2009-09-24       Impact factor: 4.035

9.  Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood.

Authors:  Massimiliano Don; Francesca Valent; Matti Korppi; Edmondo Falleti; Alessandro De Candia; Lolita Fasoli; Alfred Tenore; Mario Canciani
Journal:  Scand J Infect Dis       Date:  2007

10.  Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD.

Authors:  Mona Bafadhel; Tristan W Clark; Carlene Reid; Marie-Jo Medina; Sally Batham; Michael R Barer; Karl G Nicholson; Christopher E Brightling
Journal:  Chest       Date:  2010-10-28       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.